Mode
Text Size
Log in / Sign up
Phase 3 N=33 Treatment

Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration

Bilateral Middle Ear Effusion

Enrolled (actual)
33
Serious AEs
0.0%
Results posted
Sep 2020
Primary outcome: Primary: Otoscopic Examination: Auricle and Meatus — 1 ears

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
OTO-201 (Drug)
Age
Pediatric · 0+ yrs
Sex
All
Sponsor
Otonomy, Inc.
Primary completion
Mar 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Otoscopic Examination: Auricle and Meatus
1
PRIMARY
Otoscopic Examination: Tympanic Membrane
2
PRIMARY
Otoscopic Examination: Tube Patency
32
SECONDARY
Feasibility of Administration
29

Summary

This is a 1-month, prospective, multicenter, open-label study in pediatric subjects with bilateral middle ear effusion requiring tympanostomy tube placement. Eligible subjects will receive a single dose to each ear of 6 mg OTO-201, administered intraoperatively into the middle ear through the lumen of the tympanostomy tube (trans-tympanostomy tube TTT). The study is designed to characterize safety and any procedural issues associated with TTT drug administration of OTO-201.

Eligibility Criteria

Inclusion Criteria includes, but is not limited to:

  • Subject is a male or female aged 6 months to 17 years, inclusive
  • Subject has a clinical diagnosis of bilateral middle ear effusion requiring tympanostomy tube placement
  • Subject's caregiver is willing to comply with the protocol an attend all study visits

Exclusion Criteria includes, but is not limited to:

  • Subject has a history of prior ear or mastoid surgery, not including myringotomy or myringotomy with tympanostomy tube placement
  • Subject has a history of sensorineural hearing loss
  • Subject has been designated for any other surgical procedure that would occur concurrently with TT placement, such as, but not limited to adenoidectomy or tonsillectomy
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02350998). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search